214/262 Complete Regression Abscopal Effect The abscopal effect is a phenomenon in the treatment of metastatic cancer where localized treatment of a tumor causes not only a shrinking of the treated tumor, but also a shrinking of tumors outside the scope of the localized treatment. 214 is a much more effective drug than 262 single to single agent. Combined the cure.
When do we get the 214 data? 6 out of 10 mice tumor free. Big insider purchase. The spring is coiled tight my friends.
CNN today article that little evidence that marijuana helps with chronic pain
Watching Zacks say this "Nektar reported wider-than-expected loss in the second quarter of 2017 with revenue missing estimates." so they are lowered to HOLD ? I've always found this most amusing.... gosh their just not making $$$ ...No #$%$ SherlockGuys and girls ... Nektar should alway be a "hold" for the very nature of it's path is currently unknown and you invest with great risk that's why we are here this is not Ford, Pfizer etc...it's experimental at best , Nektar own guidance on profitability is way out which must be not well understood by Zacks and many others Zacks and the like use very old investing overviews that really don't fit wants happening.Weird to see many other so called "Top Wall Street Asset Managers" stake a claim in Nektar lately only to see Zacks say the polar opposite .. their buying Zacks moves to hold so with that we see many still staying out of the markets because analyst are only about he fruits of the tree and none about the seeds.So who see this Zacks thing and says.... I'm selling cuz the "hold" is a sell ... I imagine other analyst get a big chuckle from this. "Hold" should be removed from the experimental endeavors because they spend a lot and the target moves wildly Cheers
Form 4 posted. Looks like Roy Whitfield, director, purchased 35,000 shares on the open market last week. Is that correct?
NKTR Investor Corporate Presentation was updated in Aug 2017. 214 all new - lays out the development going forward. The 214/262 mouse data slide title is worth a long long long look (same data, stronger wording) A few PRs will be coming out in Q3 2017.
181 CIII or better.
This presentation is worth 10pps in it own.
I think see moves PDQ to $24
Looks like the CHMP meeting agenda will be available on Sept. 11.
Per the 10-Q, On July 26, 2017, we filed a request for re-examination of the opinion adopted by the CHMP (the “CHMP Appeal” ). The next CHMP meeting is 11-14 Sept, no agenda yet.
all ready know
Trade Tip...News is leaking for positive Phase 3 data to be released by Monday. Stock price is beginning to rise on the leak. Cancer/Leukemia drug will spike big time upon press release.
VSTM $3.16 +0.01 (+0.31%) Duvelisib - DUO Cancer - relapsed/refractory chronic lymphocytic leukemia (CLL) Phase 3
08/31/2017 Phase 3 data due late summer 2017.
this company is nothing more than promise, potential and hype .... no substance other than their high octane ex-lax. either the products will fail or big pharma will beat them to the punch .. guaranteed
Any thoughts on Teva drug- CIMA combines three physical and chemical barriers (gelling, barrier and matrix) as a deterrent against the main forms of abuse: Crushing for snorting, IV extraction and dose dumping in alcohol. We are developing a broad abuse deterrent opioid portfolio based on CIMA technology.
214 Combo scheduling - weaker dose every 2 weeks and stronger dose every 3 weeks. Still trying to find the optimized regiment. It may be both are required.
While seeing Roy (a director) purchase shares which all looks great a gives out a positive affirmation about the company in the current state, rest assured that directors buying shares have been met with attempted lawsuits because it was seen as false advertising even if "the person" made no comment at all..... along with knowing that Wall Street puts out bogus research with no lawsuit impact
Opioid crisis declared a national emergency.
finally a director buying big time. family trust a true believer
Bristol-Myers Squibb Co. (BMY) shares were down 0.62% to $57.52 in early morning trading Wednesday after the company announced that its kidney cancer drug trial failed to show efficacy during trials. The company said that while patients responded well during the late-stage study of its kidney cancer drugs Opdivo and Yervoy,YERVOY® (ipilimumab).
My take on the conference call.
1. It seemed JPM was impressed and is going to want more of this action. 2. There is not going to be any more dilution. They've got ~$500M cash, not including the big up front payment from a181 deal. And the present royalties and future milestone payments from 348 and 181 will keep the coffers full for years to come. 3. Looks like there is more good data in store for 214 and that they have a pathway to an early approval in the refractory indications or sarcoma. Looking forward to the updated data later this year. 4. If 348 pans out, it is going to be a great cash cow for NKTR. 5. The combination of 214 and 262 is going to be the grand slam for NKTR. 6. Oncology is a market that NKTR can manage themselves since the customer comes to them. You don't need big pharma to participate there. The NKTR game plan therefore is excellent.
I have been investing in biotech for over 20 years. I have to say that this is the best deal I've ever seen from a risk/reward basis. And I thought, at one point, that Pharmacyclics was going to be the best ever. I have to say that NKTR is going to beat it. Pharmacyclics only had one drug, Imbruvica, and they got taken out by ABBV for 250 or some odd dollars a share.
Preclinical studies underway with NKTR-214 and vaccines with potential for clinical advancement in 2018